ANA PAULA MARTE CHACRA
Índice h a partir de 2011
9
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Update of the Brazilian Guideline for Familial Hypercholesterolemia-2021(2021) IZAR, Maria Cristina de Oliveira; GIRALDEZ, Viviane Zorzanelli Rocha; BERTOLAMI, Adriana; SANTOS FILHO, Raul Dias dos; LOTTENBERG, Ana Maria; ASSAD, Marcelo Heitor Vieia; SARAIVA, Jose Francisco Kerr; CHACRA, Ana Paula M.; MARTINEZ, Tania L. R.; BAHIA, Luciana Ribeiro; FONSECA, Francisco Antonio Helfenstein; FALUDI, Andre Arpad; SPOSITO, Andrei C.; CHAGAS, Antonio Carlos Palandri; JANNES, Cinthia Elim; AMARAL, Cristiane Kovacs; ARAUJO, Daniel Branco de; CINTRA, Dennys Esper; COUTINHO, Elaine dos Reis; CESENA, Fernando; XAVIER, Hermes Toros; MOTA, Isabela Cardoso Pimentel; GIULIANO, Isabela de Carlos Back; FARIA, Jose Rocha; KATO, Juliana Tieko; BERTOLAMI, Marcelo Chiara; MINAME, Marcio Hiroshi; CASTELO, Maria Helane Costa Gurgel; LAVRADOR, Maria Silvia Ferrari; MACHADO, Roberta Marcondes; SOUZA, Patricia Guedes de; ALVES, Renato Jorge; MACHADO, Valeria Arruda; SALGADO FILHO, Wilson
- Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017(2017) FALUDI, A. A.; IZAR, M. C. O.; SARAIVA, J. F. K.; CHACRA, A. P. M.; BIANCO, H. T.; AFIUNE NETO, A.; BERTOLAMI, A.; PEREIRA, A. C.; LOTTENBERG, A. M.; SPOSITO, A. C.; CHAGAS, A. C. P.; CASELLA-FILHO, A.; SIMAO, A. F.; ALENCAR FILHO, A. C.; CARAMELLI, B.; MAGALHAES, C. C.; MAGNONI, D.; NEGRAO, C. E.; FERREIRA, C. E. S.; SCHERR, C.; FEIO, C. M. A.; KOVACS, C.; ARAUJO, D. B.; CALDERARO, D.; GUALANDRO, D. M.; MELLO JUNIOR, E. P.; ALEXANDRE, E. R. G.; SATO, I. E.; MORIGUCHI, E. H.; RACHED, F. H.; SANTOS, F. C.; CESENA, F. H. Y.; FONSECA, F. A. H.; FONSECA, H. A. R.; XAVIER, H. T.; PIMENTEL, I. C.; GIULIANO, I. C. B.; ISSA, J. S.; DIAMENT, J.; PESQUERO, J. B.; SANTOS, J. E.; FARIA NETO, J. R.; MELO FILHO, J. X.; KATO, J. T.; TORRES, K. P.; BERTOLAMI, M. C.; V, M. H. Assad; MINAME, M. H.; SCARTEZINI, M.; FORTI, N. A.; COELHO, O. R.; MARANHAO, R. C.; SANTOS FILHO, R. D.; ALVES, R. J.; CASSANI, R. L.; BETTI, R. T. B.; CARVALHO, T.; MARTINEZ, T. L. R.; GIRALDEZ, V. Z. R.; SALGADO FILHO, W.
- Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)(2017) BERTOLUCI, Marcello Casaccia; MOREIRA, Rodrigo Oliveira; FALUDI, Andre; IZAR, Maria Cristina; SCHAAN, Beatriz D.; VALERIO, Cynthia Melissa; BERTOLAMI, Marcelo Chiara; CHACRA, Ana Paula; MALACHIAS, Marcus Vinicius Bolivar; VENCIO, Sergio; SARAIVA, Jose Francisco Kerr; BETTI, Roberto; TURATTI, Luiz; FONSECA, Francisco Antonio Helfenstein; BIANCO, Henrique Tria; SULZBACH, Marta; BERTOLAMI, Adriana; SALLES, Joao Eduardo Nunes; HOHL, Alexandre; TRUJILHO, Fabio; LIMA, Eduardo Gomes; MINAME, Marcio Hiroshi; ZANELLA, Maria Teresa; LAMOUNIER, Rodrigo; SA, Joao Roberto; AMODEO, Celso; PIRES, Antonio Carlos; SANTOS, Raul D.Background: Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. Main body: The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. Conclusions: Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.
- Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil(2017) SILVA, Pamela R. S.; JANNES, Cinthia E.; OLIVEIRA, Theo G. M.; MINAME, Marcio H.; ROCHA, Viviane Z.; CHACRA, Ana Paula; GURGEL, Maria Helane C.; MONTENEGRO, Renan M.; RODRIGUES SOBRINHO, Carlos Roberto M.; MOREIRA, Annie Seixas Bello; ASSAD, Marcelo H. V.; PINTO, Marina R. C.; TADA, Mauricio Teruo; SANTOS, Raul D.; PEREIRA, Alexandre C.; KRIEGER, Jose E.Background and aims: There is controversy on the accuracy of different diagnostic criteria for familial hypercholesterolemia (FH). The aim of this study is to assess the performance of different clinical criteria used to identify individuals for FH genetic cascade screening in Brazil. Methods: All index cases (IC) registered in the Hipercol Brasil program between 2011 and 2016 were analyzed. Inclusion criteria were age > 18 years and elevated LDL-cholesterol (LDL-C) levels, with a conclusive result in the genetic test, whether positive or negative. Initially, we tested the multivariable association between clinical and laboratory markers and the presence of an FH causing mutation. Then, we analyzed sensitivity, specificity, positive and negative predictive values for the LDL-C quartile distribution, LDL-C as a continuous variable, as well as the performance measures for the Dutch Lipid Clinic Network (DLCN) score to identify a mutation. Results: Overall, 753 ICs were included and an FH causing mutation was found in 34% (n = 257) of the subjects. After multivariable analysis, LDL-C as a continuous variable, tendon xanthomas and corneal arcus were independently associated with the presence of FH mutations. LDL-C values >= 230 mg/dL (5.9 mmol/L) had the best tradeoff between sensitivity and specificity to diagnose a mutation. The DLCN score presented a better performance than LDL-C to identify a mutation, area under the ROC curve were 0.744 (95% CI: 0.704-0.784) and 0.730 (95% CI: 0.687-0.774), respectively, p = 0.014. Conclusions: In our population, LDL >= 230 mg/dL is a feasible criterion to indicate ICs to genetic testing. (C) 2017 Published by Elsevier Ireland Ltd.